

## Clinical researches

### MULTICENTRIC STUDIES

#### Completed

- PI for: QUASAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. 2023-2025. Completed.
- S-I for: SANDCAT (Roche) - A Phase III, Multicenter, Randomized, Double Masked, Sham-controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Anti-IL6 in Adult Patients with Uveitic Macular Edema. 2024-2025. Completed.
- PI for: PULSAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Multi-Center Study of Efficacy and Safety of Intravitreal High Dose Aflibercept (8 mg) in Patients with Neovascular Age-Related Macular Degeneration. 2021-2024. Completed.
- INTERCEPT (Aibili) - A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate AMD with and without Early Atrophy to Study Prediction of Disease Progression. Collaboration with: EVICR.net; 2023. Completed.
- Multicentric Retrospective Study on Response to Brolucizumab in Treatment-naïve and Pre-treated Eyes Diagnosed with Wet AMD. Collaboration with: Berner Augenklinik am Lindenhofspital; 2022. Completed.
- Consensus Visual OCT Priming Study Wet AMD. In collaboration with: Institute of Molecular and Clinical Ophthalmology Basel, the University Hospital Basel and the University of Applied Sciences Northwestern Switzerland; 2022. Completed.
- Global nAMD & DR Barometer Survey - A multi-country patient and clinician survey to investigate patients' and clinical peers' perspectives, trends and practice patterns, relevant to the delivery of care for nAMD and DR. 2022. Completed.
- Real-Life Outcomes of Adjunct Intravitreal Dexamethasone Implant (Ozurdex) in Patients Treated with anti-VEGF Drugs for Diabetic Macular Edema and Exudative Age-Related Macular Degeneration. In collaboration with: Berner Augenklinik am Lindenhofspital; 2022. Completed.
- PI for: FALCON (Novartis) - A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled neovascular age-related macular degeneration. 2021-2022. Completed.
- PI for: The brolucizumab RAPTOR BRVO study RTH258C2301 (Novartis) - An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. 2019-2021. Completed.
- PI for: XTEND (Bayer) – Evaluation of an eXtended and proacTive dosing regimen in treatment-Naïve patients with wet age-related macular Degeneration (wAMD). 2019. Completed.
- PI for: (Oxurion) - A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment of diabetic macular oedema. 2018-2019. Completed.
- PI for: Allergan Abicipar Pegol 150998-005 (CEDAR) Study: The Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age related Macular Degeneration. 2016-2017. Completed.
- S-PI for: Efficacy and Safety of RTH258 versus Aflibercept Long Title A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. 2015-2017. Completed.
- PI for: MONT BLANC - A 12-month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs.

verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Completed.

- PI for: RADIANCE - A 12-month phase III study to evaluate efficacy and safety of two different dosing regimens of 0.5mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal CNV secondary to pathologic myopia. Completed.
- S-PI for: A phase 3, randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration Fovista. Completed.
- S-PI for: OCTAVE - A 24-month phase IIIb randomized multicenter study assessing safety and efficacy of two treatment regimens of 0.5mg ranibizumab intravitreal guided by functional and /or anatomical criteria in patients with neovascular AMD. Completed.
- S-PI for: A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration. Completed.
- S-PI for: PROMETEUS - A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME). Completed.
- S-PI for: MINERVA - A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). Completed.
- PI for: CRYSTAL - A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Completed.
- PI for: BRIGHTER - A 24-month, phase IIIb, open-label, randomized, active controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). Completed.

## Ongoing

- PI for: GALAXY (ONL Therapeutics) - A Phase 2 Multicenter, Randomised, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients with Geographic Atrophy (GA) Associated with Age-related Macular Degeneration (AMD). Ongoing.
- PI for: Real-Life Outcomes in Diabetic Macular Edema and Exudative Age-Related Macular Degeneration treated with Faricimab and/or Aflibercept 8mg. Ongoing.
- PI for: VOYAGER (Roche) - Real-world, Long-term Data Collection to Gain Clinical Insights into Roche Ophthalmology Products. Ongoing.
- PI for: SPECTRUM (Bayer) - An Observational Study Program to Investigate the Effectiveness of Aflibercept 8mg Used in nDME and nAMD in a Real-world Setting. Ongoing.
- PI for: AI-based Analysis of Retinal Imaging Data of Real-World Evidence in Switzerland. Ongoing.

## MONOCENTRIC STUDIES

### Completed

- Intravitreal Faricimab in Patients Treated for Refractory Diabetic Macular Edema. 2023-2025. Completed.
- Efficacy and Durability of Faricimab Intravitreal Injections in Naïve Patients With Wet Age-related Macular Degeneration. 2023-2025. Completed.
- Switch From Aflibercept to Faricimab in Patients With Neovascular Age-related Macular De-generation. 2023-2025. Completed.
- Evolution of Acute Intraocular Pressure Elevations Following Intravitreal Anti-VEGF Injections Over One Year of Treatment.
- Influence of Structural Spectral-domain Optical Coherence Tomography Characteristics in the Detection of Choroidal Neovascularization Due to Age-related Macular Degeneration Using Op-tical Coherence To-mography Angiography.
- COVID AMD - Tsiropoulos GN, Ambresin A. Patient Opinion on the Monitoring of Their Wet Age-related Macular Degeneration During Coronavirus Disease 2019 Pandemic and on the Im-portance of Telemedi-cine. Free paper.
- COVID AMD - The Importance of Monitoring Wet AMD Patients During Covid-19 Pandemic: a Retrospec-tive Study of Assessment of Functional and Structural Outcomes. Published.
- COVID-RV – Five Cases of Retinal Vascular Anomalies After Covid-19: a Case Series. Free paper.
- Fovea Plana / Hypoplasia - Foveal Hypoplasia on Optical Coherence Tomography Angiography: New Per-spectives. Published.
- AZM RD - Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dys-trophy Treated with Oral Acetazolamide: Two Cases. Published.
- Vitamin A Deficiency - Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Sec-ondary to Bowel Resection. Published.

### Ongoing

- Photobiomodulation (PBM) therapy in intermediate dry age-related macular degeneration (AMD). 2025-ongoing.
- DREAM OCT - Noninvasive ultrawide field choroidal imaging using swept source OCT to assess macular and peripheral choroidal vasculature. 2025- ongoing.
- Optics-Flood Illumination (AO-FI) study of chronic retinal diseases: dry age-related macular de-generation (AMD), central serous chorioretinopathy (CSCR) and non-proliferative diabetic reti-nopathy (NPDR). 2025-ongoing.
- Evaluation of geographic atrophy (GA) lesion size and growth rates measurements using se-miautomated and artificial intelligence (AI) software. 2025-ongoing.
- Real-world observational data on the use of aflibercept 8mg intravitreal injection in patients treated for exu-dative age-related macular degeneration and diabetic macular edema. 2024-on-going.